miR-96-5p regulated TGF-β/SMAD signaling pathway and suppressed endometrial cell viability and migration via targeting TGFBR1.


Journal

Cell cycle (Georgetown, Tex.)
ISSN: 1551-4005
Titre abrégé: Cell Cycle
Pays: United States
ID NLM: 101137841

Informations de publication

Date de publication:
07 2020
Historique:
entrez: 9 7 2020
pubmed: 9 7 2020
medline: 3 9 2021
Statut: ppublish

Résumé

We previously performed high throughput RNA-seq in paired eutopic and ectopic endometrial specimen of endometriosis patients, and validated the results by qRT-PCR in endometriosis endometrial tissues. MiR-96-5p was significantly downregulated in ectopic endometrial tissues compared to eutopic tissues. In order to identify the role of miR-96-5p in endometriosis and endometrial cells, and investigate the underlying mechanisms, the Ishikawa and End1/E6E7 cell lines were transfected with miR-96-5p mimics, miR-96-5p inhibitors or TGFBR1 siRNA. The expression of TGF-β/SMAD signaling pathway components and epithelial-mesenchymal transition (EMT) markers were examined by qRT-PCR and western blot, and cell viability and migration were determined by CCK-8, transwell and wound healing assays, respectively. We discovered miR-96-5p to be significantly downregulated while TGFBR1 was distinctly up-regulated in endometriosis. Overexpression of miR-96-5p inhibited endometrial cells viability and migration, while inhibition of miR-96-5p had opposite effect. Furthermore, we confirmed TGFBR1 was a direct target of miR-96-5p. Overexpression of miR-96-5p could block the TGF-β/SMAD signaling pathway via targeting TGFBR1 and reverse the TGF-β1 induced EMT in endometrial cell lines. In conclusion, we demonstrated that miR-96-5p interacted with TGF-β/SMAD signaling pathway and blocked the TGF-β1 induced EMT in endometrial cells via directly targeting TGFBR1.

Identifiants

pubmed: 32635855
doi: 10.1080/15384101.2020.1777804
pmc: PMC7469441
doi:

Substances chimiques

MIRN96 microRNA, human 0
MicroRNAs 0
Smad Proteins 0
Transforming Growth Factor beta1 0
Receptor, Transforming Growth Factor-beta Type I EC 2.7.11.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1740-1753

Références

Int J Clin Exp Pathol. 2015 Sep 01;8(9):9889-900
pubmed: 26617698
Chin Med J (Engl). 2017 Apr 20;130(8):950-956
pubmed: 28397725
N Engl J Med. 2010 Jun 24;362(25):2389-98
pubmed: 20573927
Curr Opin Genet Dev. 2005 Oct;15(5):563-8
pubmed: 16099643
J Exp Clin Cancer Res. 2015 Sep 29;34:107
pubmed: 26419932
Oncol Lett. 2018 May;15(5):7689-7692
pubmed: 29725467
Trends Immunol. 2010 Jun;31(6):220-7
pubmed: 20538542
Life Sci. 2018 Jun 15;203:1-11
pubmed: 29656060
Mol Carcinog. 2015 Nov;54(11):1442-50
pubmed: 25256312
Front Oncol. 2017 Jul 05;7:145
pubmed: 28725636
Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3421-3430
pubmed: 31081096
Mol Genet Genomic Med. 2019 Jul;7(7):e00756
pubmed: 31144476
Nat Rev Cancer. 2010 Jun;10(6):415-24
pubmed: 20495575
Cancer Sci. 2015 May;106(5):481-8
pubmed: 25664423
Int J Mol Med. 2014 Dec;34(6):1599-605
pubmed: 25242509
Lancet. 2004 Nov 13-19;364(9447):1789-99
pubmed: 15541453
Biol Reprod. 2019 May 1;100(5):1135-1146
pubmed: 30721951
PLoS One. 2014 Sep 10;9(9):e106773
pubmed: 25207642
Int J Mol Sci. 2018 Feb 17;19(2):
pubmed: 29463003
Cancer Cell Int. 2015 Nov 14;15:107
pubmed: 26582573
Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:25-33
pubmed: 30245115
Int J Oncol. 2018 Jul;53(1):237-245
pubmed: 29658604
Clin Cancer Res. 2013 Mar 1;19(5):1213-24
pubmed: 23362326
Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:1-15
pubmed: 30017581
Int J Mol Sci. 2018 Jul 20;19(7):
pubmed: 30037059
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Reprod Sci. 2016 Feb;23(2):186-91
pubmed: 26516123
Hum Reprod. 1996 Apr;11(4):878-80
pubmed: 8671344
Nature. 1997 Dec 4;390(6659):465-71
pubmed: 9393997
Reprod Sci. 2016 Oct;23(10):1359-70
pubmed: 27412772
J Vasc Res. 2020;57(2):86-96
pubmed: 32045906
Immunol Lett. 2018 Sep;201:31-37
pubmed: 30367890

Auteurs

Silei Chen (S)

Department of Obstetrics & Gynecology, Shengjing Hospital of China Medical University , Shenyang, China.

Yajuan Luo (Y)

Department of Obstetrics & Gynecology, Shengjing Hospital of China Medical University , Shenyang, China.

Liangyi Cui (L)

Department of Obstetrics & Gynecology, Shengjing Hospital of China Medical University , Shenyang, China.

Qing Yang (Q)

Department of Obstetrics & Gynecology, Shengjing Hospital of China Medical University , Shenyang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH